ETI60

ETI60 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 (IC50 = 0.68 μM) and TLR9 (IC50 = 0.12 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5) . ETI60 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI60 modulates the expression of genes associated with inflammation. ETI60 effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE) . ETI60 can be used for autoimmune and inflammatory diseases research[1].

Product Specifications

CAS Number

[2773475-11-7]

UNSPSC

12352005

Target

ERK; Interleukin Related; JNK; NF-κB; p38 MAPK; TNF Receptor; Toll-like Receptor (TLR)

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

NC1=C(C(C=CC(OC)=C2)=C2N3CCCN(C)C)C3=NC4=C1CCCC4

Molecular Formula

C21H28N4O

Molecular Weight

352.47

References & Citations

[1]Jeong U, et al. Discovery of ETI41 and ETI60: novel selective endosomal Toll-like receptor inhibitors for the treatment of autoimmune diseases. Exp Mol Med. 2025 Sep;57 (9) :1951-1962.